Home Page

Lysaker, 27 November 2015 - In accordance with the authorization granted by the Annual General Meeting 13th May 2014, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 110,000 options to key employees. Each option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA's choice), at a strike price of NOK 5.21, equal to the volume weighted average price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The options are lapsing in Q3 2020.

Of these options, 9,000 options were allotted to Per Walday, CEO. After the allocation, Per Walday holds a total portfolio of 105,000 unexercised options and 44,019 shares.

7,500 options were allotted to Kristin Eivindvik, PD. After the allocation, Kristin Eivindvik holds a total portfolio of 24,500 unexercised options and 13,235 shares.

6,000 options were allotted to Gaël L'Hévéder, CBDO. After the allocation, Gaël L'Hévéder holds a total portfolio of 91,000 unexercised options and 10,000 shares.

6,000 options were allotted to Anders Høgset, CSO. After the allocation, Anders Høgset holds a total portfolio of 77,000 unexercised options and 47,977 shares.

6,000 options were allotted to Ronny Skuggedal, CFO. After the allocation, Ronny Skuggedal holds a total portfolio of 66,000 unexercised options and 15,000 shares.

For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.